MSLE6:30 AMSatellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247Interim Datasatellos.com
MSLE7:00 AMSatellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophysatellos.com
MSLE7:00 AMSatellos Reports First Quarter 2026 Financial Results and Highlights Company Progresssatellos.com